BioSpace

Zealand Pharma is looking to build on last week’s positive Phase Ib trial results by raising around $1 billion in a public offering, with the proceeds being used to advance its obesity candidates. #pharma #biospace https://hubs.li/Q02DpMgH0

Teva Pharmaceuticals has settled years of tax litigation with the Israel Tax Authority for $750 million, which the company will pay in installments starting in 2024 to 2029. #pharma #biospace https://hubs.li/Q02Dpv5r0

Following in the footsteps of Sanofi and Moderna, Eli Lilly and Company on Tuesday inked a collaboration agreement with OpenAI to develop novel antimicrobial agents against drug-resistant pathogens. #AI #tech #biospace https://hubs.li/Q02Dpv0L0

One patient died of respiratory failure in a Phase I study of Lyell Immunopharma’s investigational CAR-T therapy. The company on Wednesday said it has not definitively linked the fatality to the treatment. #CART #biospace https://hubs.li/Q02DplRb0

This week, BioSpace's Heather McKenzie, Greg Slabodkin and Tyler Patchen discuss the expanded approval of Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys, Alnylam Pharmaceuticals' high stakes ATTR-CM win and highlights from ADA. #podcast #biospace https://hubs.li/Q02DnWXB0

Continuing investment in basic infectious disease research and pandemic preparedness infrastructure isn’t just about being ready for the next pandemic—it’s also a smart business move. #investment #biospace https://hubs.li/Q02DnYXH0

After winning expanded approval for its gene therapy for Duchenne muscular dystrophy, Sarepta Therapeutics' leadership and analysts see a sizeable commercial opportunity on the horizon. #sarepta #biospace https://hubs.li/Q02Dn-Dn0

The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue. #pharma #biospace https://lnkd.in/gC5aUz8T

Join us in Boston for this insightful and informative event - Regulatory Agility: The Intersection of AI and QARA. IQVIA and a variety of panelists will explore the dynamic landscape where AI meets regulatory excellence including:   ▪ The benefits of a connected quality & regulatory ecosystem ▪ Applying #AI in today’s reality of QARA processes ▪ Positioning #QARA as a market access function in globalization.   Panelists include experts from: AbbVie, Baxter International Inc., Microsoft, Phillips, YourBio Health, Cynosure, LLC., Lucid Diagnostics, Olympus Corporation of the Americas, Bristows LLP,  AVAVA, Inc., Blossom Innovations, Boyd Medical Inc., and Foley Hoag LLP. BioSpace's Lori Ellis (Katz) will be moderating the day's discussions.   Click here to see full event details and register! https://lnkd.in/gMhPAeK6

Following success in several indications including ulcerative colitis, Johnson & Johnson’s blockbuster drug Tremfya failed to meet a mid-stage study’s primary endpoint in treating giant cell arteritis. #biopharma #biospace https://lnkd.in/ga22mMVe